ArticleCureus2026
Persistent HyperCKemia Beyond Post-Viral Myositis: A Case of Anti-HMGCR Immune-Mediated Necrotizing Myopathy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) immune-mediated necrotizing myopathy (IMNM) is a rare autoimmune myopathy that should be suspected in patients with progressive proximal muscle weakness and marked creatine kinase (CK) elevation persisting despite statin discontinuation, although distinguishing it from more common conditions such as post-viral myositis and toxic statin-associated myopathy remains a major diagnostic challenge. We report the case of a 64-year-old man receiving long-term atorvastatin therapy who presented with progressive proximal muscle weakness, dysphagia, and severe hyperCKemia following a self-limited flu-like illness, initially raising post-viral myositis as the leading hypothesis. Despite immediate statin discontinuation and aggressive intravenous hydration, severe hyperCKemia persisted during the first week of supportive management alone, and the neurological deficits did not improve, prompting further investigation and empirical immunosuppression. Muscle magnetic resonance imaging demonstrated multifocal inflammatory muscle edema, while extensive investigation for infectious, metabolic, endocrine, neoplastic, and autoimmune causes was unrevealing. Muscle biopsy showed a necrotizing myopathy with pauci-inflammatory features, and anti-HMGCR antibodies, which had not been included in the initial extended myositis panel and required a dedicated request, were subsequently identified, confirming statin-associated IMNM. Treatment with high-dose corticosteroids followed by methotrexate produced progressive biochemical improvement and complete recovery of muscle strength and swallowing function, with CK falling to 376 U/L (N 30-200 U/L) at the last follow-up (four months after admission). The principal educational value of this case lies in the diagnostic reasoning rather than in the diagnosis itself: it was the failure of the clinical and biochemical course to follow the anticipated trajectory, rather than the initial presentation, that prompted reconsideration of the working hypothesis. Dysphagia, less commonly reported in post-viral myositis and toxic statin-associated myopathy, together with persistent severe hyperCKemia despite statin withdrawal, should prompt evaluation for anti-HMGCR IMNM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.